Considering that NLRP3 inflammasome inhibition may be a potential target for the treatment of invasive BC, Yan H. et al. treated invasive BC using cisplatin to induce scorching via activation of the maternally expressed gene 3/NLRP3/caspase‐1/GSDMD pathway in triple‐negative breast cancer (TNBC). Here, NLRP3 is linked to breast cancer.